Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform

BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market New board leadership reflects Field's momentum and readiness for pivotal executionand X.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.

Media Contact
Holly Windler
holly.windler@gmail.com

Photo - https://mma.prnewswire.com/media/2722619/Field_Medical_FieldForce__Ablation_System_Next_generation_PFA.jpg
Logo - https://mma.prnewswire.com/media/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/field-medical-closes-oversubscribed-35-million-series-b-to-advance-development-of-fieldforce-pulsed-field-ablation-platform-302495701.html

en | boerse | 67934555 |